BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stritzelberger J, Distel L, Buslei R, Fietkau R, Putz F. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine. Clin Transl Oncol 2018;20:508-16. [PMID: 28825189 DOI: 10.1007/s12094-017-1743-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Bloom M, Maciaszek JL, Clark ME, Pui CH, Nichols KE. Recent advances in genetic predisposition to pediatric acute lymphoblastic leukemia. Expert Rev Hematol 2020;13:55-70. [PMID: 31657974 DOI: 10.1080/17474086.2020.1685866] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
2 Yamamuro S, Takahashi M, Satomi K, Sasaki N, Kobayashi T, Uchida E, Kawauchi D, Nakano T, Fujii T, Narita Y, Kondo A, Wada K, Yoshino A, Ichimura K, Tomiyama A. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. Cancer Sci 2021. [PMID: 34536314 DOI: 10.1111/cas.15141] [Reference Citation Analysis]
3 Wang J, Zuo J, Wang MD, Xie WF, Bai XB, Ma XD. Retraction: Receptor tyrosine kinase AXL is correlated with poor prognosis and induces temozolomide resistance in glioblastoma. CNS Neurosci Ther 2020;26:777. [PMID: 31578804 DOI: 10.1111/cns.13227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Pui CH, Nichols KE, Yang JJ. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol 2019;16:227-40. [PMID: 30546053 DOI: 10.1038/s41571-018-0136-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 21.0] [Reference Citation Analysis]
5 Xiong J, Guo G, Guo L, Wang Z, Chen Z, Nan Y, Cao Y, Li R, Yang X, Dong J, Jin X, Yang W, Huang Q. Amlexanox Enhances Temozolomide-Induced Antitumor Effects in Human Glioblastoma Cells by Inhibiting IKBKE and the Akt-mTOR Signaling Pathway. ACS Omega 2021;6:4289-99. [PMID: 33644550 DOI: 10.1021/acsomega.0c05399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kebudi R, Amayiri N, Abedalthagafi M, Rana AN, Kirmani S, Musthaq N, Lamki ZA, Houdzi JE, Yazici H, El-Naggar S, Edwards M, Bianchi VJ, Durno C, Tabori U, Bouffet E; International RRD Consortium on Low-Resource Settings Panel. Position paper: Challenges and specific strategies for constitutional mismatch repair deficiency syndrome in low-resource settings. Pediatr Blood Cancer 2020;67:e28309. [PMID: 32472748 DOI: 10.1002/pbc.28309] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer 2021;1876:188616. [PMID: 34419533 DOI: 10.1016/j.bbcan.2021.188616] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lozinski M, Bowden NA, Graves MC, Fay M, Tooney PA. DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets. Cell Oncol (Dordr) 2021. [PMID: 34057732 DOI: 10.1007/s13402-021-00613-0] [Reference Citation Analysis]
9 Gallitto M, Cheng He R, Inocencio JF, Wang H, Zhang Y, Deikus G, Wasserman I, Strahl M, Smith M, Sebra R, Yong RL. Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1. J Neurooncol 2020;147:557-66. [PMID: 32193690 DOI: 10.1007/s11060-020-03461-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res 2021;171:105780. [PMID: 34302977 DOI: 10.1016/j.phrs.2021.105780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 McPherson KS, Korzhnev DM. Targeting protein-protein interactions in the DNA damage response pathways for cancer chemotherapy. RSC Chem Biol 2021;2:1167-95. [PMID: 34458830 DOI: 10.1039/d1cb00101a] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhai B, Li Y, Kotapalli SS, Bacha J, Brown D, Steinø A, Daugaard M. Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells. Cell Death Dis 2020;11:577. [PMID: 32709853 DOI: 10.1038/s41419-020-02780-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Yuan AL, Meode M, Tan M, Maxwell L, Bering EA, Pedersen H, Willms J, Liao J, Black S, Cairncross JG, Blough MD. PARP inhibition suppresses the emergence of temozolomide resistance in a model system. J Neurooncol 2020;148:463-72. [PMID: 32562246 DOI: 10.1007/s11060-020-03561-1] [Reference Citation Analysis]
14 Chelliah SS, Paul EAL, Kamarudin MNA, Parhar I. Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas. Molecules 2021;26:1169. [PMID: 33671796 DOI: 10.3390/molecules26041169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Alafate W, Xu D, Wu W, Xiang J, Ma X, Xie W, Bai X, Wang M, Wang J. Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling. J Exp Clin Cancer Res 2020;39:239. [PMID: 33176854 DOI: 10.1186/s13046-020-01750-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM, Costello JF. Temozolomide-associated hypermutation in gliomas. Neuro Oncol 2018;20:1300-9. [PMID: 29452419 DOI: 10.1093/neuonc/noy016] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 18.7] [Reference Citation Analysis]
17 Ha W, Sevim-Nalkiran H, Zaman AM, Matsuda K, Khasraw M, Nowak AK, Chung L, Baxter RC, McDonald KL. Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF). Sci Rep 2019;9:2905. [PMID: 30814573 DOI: 10.1038/s41598-019-39427-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
18 Alafate W, Wang M, Zuo J, Wu W, Sun L, Liu C, Xie W, Wang J. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide. Pathology - Research and Practice 2019;215:152617. [DOI: 10.1016/j.prp.2019.152617] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Yu X, Wang M, Zuo J, Wahafu A, Mao P, Li R, Wu W, Xie W, Wang J. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Life Sci 2019;236:116917. [PMID: 31614149 DOI: 10.1016/j.lfs.2019.116917] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
20 Bryukhovetskiy I, Pak O, Khotimchenko Y, Bryukhovetskiy A, Sharma A, Sharma HS. Personalized therapy and stem cell transplantation for pro-inflammatory modulation of cancer stem cells microenvironment in glioblastoma: Review. Int Rev Neurobiol 2020;151:67-98. [PMID: 32448615 DOI: 10.1016/bs.irn.2020.03.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]